EN DE
Watch Biofrontera AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biofrontera AG (B8FK) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Biofrontera AG stock €1.35, price €3.02, that is 55.3% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE

BA Biofrontera AG logo Thin data Nov 8, 2026

Biofrontera AG

B8FK · XETRA
Solid, but very expensive

Our calculation puts a fair price 55% below what the stock costs today.

Highly profitable · 33.0% net margin (TTM)
Ranks above peers (6/10)
Revenue last quarter +78% vs. a year ago.
Quality 51/100
Moderate moat 49/100 · thin data
Fair value €1.35 · Strongly overvalued
Weak Growth (revenue 5y −15.4 %/yr in EUR)
Negative free cash flow
Thin data
⚠ Small free float
Watch Biofrontera AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€54.81 €2.15 Fair Value €1.35 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range €2.15 – €54.81 · fair‑value band €0.8900 – €1.68 · the €3.02 price screens above the €1.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Biofrontera in your weekly email

Every Wednesday you see whether Biofrontera is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.

Show moreShow less

The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma.

The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.

In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma.

The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Stock analysis

Biofrontera AG (B8FK) currently trades at €3.02, while our model-based Fair Value estimate is €1.35, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.8900 (bear) to €1.68 (bull), the price of €3.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Biofrontera AG reported revenue of €13.2M in FY2025 versus €28.8M in FY2021, a compound −17.7%/yr. Reported net income was −€4.0M in FY2025.

Key figures

Market cap €18.5M Micro · P/S ratio 1.16 · EPS (TTM) €−0.2800 · Net margin −30.1% · Return on equity −36.4% · Return on assets (EBIT) −2.2% (5-year average) · Operating margin 27.3% · Revenue (TTM) €16.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −55%, B8FK screens richer than that median.

Fair Value models

Bear €0.8900 Fair Value €1.35 Bull €1.68
Price €3.02 · Downside -55.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.8900 €1.35 €1.68 52
All 1 models by family
Asset-Based
NCAV (Graham) €0.8900 €1.35 €1.68 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 28
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 65
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 52
How calm the share price moves, does not count
Price momentum 64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 43
Distance to the 52-week high, does not count
New shares 87
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.4%
Start year 2020 (pandemic). Over 10 years: +12.3% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18.5% (2020) → −7.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

B8FK screens overvalued: fair value 55% below the price. Compare with Merck KGaA →

Compare Biofrontera AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside −55.3% · Bottom 25%
Profitability
Return on assets −19.2% · Bottom 25%
Net margin (12 months) 33.0% · Top 25%
Operating margin (12 months) 27.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 78.2% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.24× · Cheaper than median
P/S (12 months) 1.16× · Cheaper than median
EV/EBITDA 7.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs B8FK
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs B8FK
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs B8FK
Haleon plc HLN $9.14 $8.61 −6% vs B8FK
Merck KGaA MRK €148.75 €109.18 −27% vs B8FK
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs B8FK
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs B8FK
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs B8FK
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs B8FK
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs B8FK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biofrontera AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biofrontera AG Fair Value". https://www.fairvalue-calculator.com/stock/B8FK

Frequently asked questions

Is Biofrontera AG (B8FK) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €1.35 versus a price of €3.02, about 55% lower (overvalued).
What is the fair value of B8FK?
Our model-based fair value for Biofrontera AG is €1.35 (as of Nov 8, 2026), built from audited fundamentals. The current price: €3.02.
What is the quality score of B8FK?
Biofrontera AG has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biofrontera AG (B8FK)?
Our model-based price target is the fair value of €1.35 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario €0.8900, optimistic scenario €1.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Biofrontera AG stock forecast for 2026?
Our models put fair value at €1.35, about 55% lower versus a price of €3.02 (overvalued). Cautious scenario €0.8900, optimistic scenario €1.68. The calculation is refreshed regularly with new filings.
What is the revenue of Biofrontera AG (B8FK)?
Biofrontera AG reported trailing-twelve-month revenue of about €16.0M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Biofrontera AG (B8FK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biofrontera AG it is €1.35 per share (as of Nov 8, 2026), against a price of €3.02. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Biofrontera AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, B8FK trades above its calculated fair value: price €3.02, fair value €1.35, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of B8FK?
No. The price is what the market pays today (€3.02); the fair value is what the company's own numbers justify (€1.35). For Biofrontera AG the two are €1.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biofrontera AG worth?
The market values Biofrontera AG at about €18.5M (market capitalisation, as of Nov 8, 2026). Per share that is €3.02; our models calculate a fair value of €1.35 per share.
What do the bullish and bearish scenarios say about B8FK?
Our models span a range for Biofrontera AG: cautious scenario €0.8900, base €1.35, optimistic €1.68 per share (as of Nov 8, 2026, price €3.02). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biofrontera AG (B8FK)?
Balance-sheet figures for Biofrontera AG (as of Nov 8, 2026): return on equity −36.4%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is B8FK from its 52-week high?
Biofrontera AG trades at €3.02, about 25% below its 52-week high of €4.04 and 34% above the low of €2.26 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.35 is for.
Which stocks are comparable to Biofrontera AG?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biofrontera AG stock attractive at the current price?
The data as of Nov 8, 2026: price €3.02, calculated fair value €1.35 (−55%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of B8FK calculated?
We run Biofrontera AG through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €1.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Biofrontera AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biofrontera AG (B8FK)?
The closing price on Nov 6, 2026 was €3.02. Our model-based fair value is €1.35, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biofrontera AG right now?
The price sits above even our optimistic bull case (€1.68). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€0.8900 to €1.68) leaves room in how you read the outcome.

Key figures of Biofrontera AG

How large is the market capitalisation of Biofrontera AG (B8FK)?
The market capitalisation of Biofrontera AG is €18.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biofrontera AG (B8FK)?
The price-to-sales ratio of Biofrontera AG is 1.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biofrontera AG (B8FK)?
Earnings per share at Biofrontera AG are €−0.2800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biofrontera AG (B8FK)?
The net margin of Biofrontera AG is −30.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biofrontera AG (B8FK)?
The return on equity (ROE) of Biofrontera AG is −36.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biofrontera AG (B8FK)?
On an EBIT basis the return on assets of Biofrontera AG is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biofrontera AG (B8FK)?
The operating margin of Biofrontera AG is 27.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biofrontera AG (B8FK)?
Revenue at Biofrontera AG is growing +78.2% versus a year earlier (3y avg −20.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biofrontera AG (B8FK)?
Earnings per share at Biofrontera AG are growing +227% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biofrontera AG (B8FK) generate?
The free cash flow of Biofrontera AG is −€4.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biofrontera AG (B8FK) hold?
Biofrontera AG holds more cash than debt, €3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Biofrontera AG in the live analysis

One click puts Biofrontera AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.